O1‐09‐04: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION (OLE) OF THE MARGUERITE ROAD STUDY IN PATIENTS WITH MILD ALZHEIMER'S DISEASE (AD) AFTER APPROXIMATELY TWO YEARS OF STUDY DURATION-Reference-Cited by-同舟云学术

O1‐09‐04: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION (OLE) OF THE MARGUERITE ROAD STUDY IN PATIENTS WITH MILD ALZHEIMER'S DISEASE (AD) AFTER APPROXIMATELY TWO YEARS OF STUDY DURATION

Published:2006-07 Issue:7S_Part_4 Volume:14 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Abi-Saab Danielle¹,Andjelkovic Mirjana¹,Pross Nathalie¹,Delmar Paul¹,Voyle Nicola²,Klein Gregory¹,Esau Nelli¹,Ristic Smiljana¹,Martenyi Ferenc¹,Fontoura Paulo¹,Doody Rachelle³⁴

Affiliation:

1. F. Hoffmann-La Roche LtdBaselSwitzerland

2. Roche Products LtdWelwyn Garden CityUnited Kingdom

3. Product Development NeuroscienceF. Hoffmann-La Roche LtdBaselSwitzerland

4. Genentech, Inc.South San FranciscoCAUSA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2018.06.2381

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease;Alzheimer's Research & Therapy;2022-11-29

3. Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease;Clinical Pharmacology & Therapeutics;2022-02-28

4. New Perspectives for Treatment in Alzheimer’s Disease;Pharmacological Treatment of Alzheimer's Disease;2022

5. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval;Alzheimer's Research & Therapy;2020-08-12